Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sponsor

USWM Ct LLC

United States 4441 Springdale Road, 40241-1086, United States

About the sponsor

USWM Ct LLC supports clinical research centered on autologous T-cell therapies and genetically modified cellular products for solid tumors. Its trial portfolio includes studies of NY-ESO-1 and LAGE-1a targeted cell therapies, with attention to tumors expressing these cancer-testis antigens.

  • Autologous genetically modified T cells
  • NY-ESO-1 and LAGE-1a positive solid tumors
  • Long-term follow-up after cell therapy

The sponsor’s research activity also includes monitoring of delayed adverse events associated with genetically modified cell products.

About Specializations

USWM Ct LLC runs clinical trials in conditions such as Myxoid liposarcoma, Synovial sarcoma, Round cell liposarcoma, Plasma cell myeloma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Plasma cell myeloma+3

Recruiting

Long-Term Follow-Up Study for Patients with Myxoid/Round Cell Liposarcoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Synovial Sarcoma Treated with Letetresgene Autoleucel

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Letetresgene Autoleucel
  • Sponsor:USWM Ct LLC

Myxoid liposarcoma+2

Not recruiting

Study of Afamitresgene Autoleucel for Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Afamitresgene Autoleucel
  • Sponsor:USWM Ct LLC

Myxoid liposarcoma+2

Not recruiting

Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Letetresgene Autoleucel
  • Sponsor:USWM Ct LLC

Ovarian cancer recurrent

Not recruiting

Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:USWM Ct LLC

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.